For your patients with overactive bladder (OAB)

MORE TIME HERE LESS TIME THERE WITH GEMTESA1

GEMTESA® is a beta-3 adrenergic agonist indicated for
the treatment of overactive bladder (OAB) with
symptoms of urge urinary incontinence, urgency, and
urinary frequency in adults.

GEMTESA® is indicated for the treatment of overactive bladder.
 
 

There's more to know about GEMTESA

Where would you like to go?

For more time wherever they want to be, prescribe GEMTESA1

Stopwatch icon.

URGENCY IMPROVEMENT

  • Proven urgency reduction data in label1
  • Statistically significant reduction of all 3 key OAB symptoms* vs placebo at 12 weeks— including urgency1,2†
  • ~43% of all OAB patients taking GEMTESA had a 50% reduction in urgency episodes at week 12 vs 38% with placebo3‡
See the efficacy results
Calendar icon.

One dose, no titration

  • Once-daily 75-mg dose with no titration, to be taken with or without food and swallowed whole with a glass of water1
  • Crushability. In adults, GEMTESA tablets may be crushed, mixed with a tablespoon (~15 mL) of applesauce and taken immediately with a glass of water1
Check out simple dosing
Heart icon. GEMTESA® is not associated with clinically significant changes in blood pressure.

NO BLOOD PRESSURE WARNING IN ITS LABEL1

  • No association with clinically significant changes to hypertension or increased blood pressure vs placebo1,3§||
View the safety data

*The 3 key symptoms of OAB are urgency, micturition frequency, and urge urinary incontinence (UUI)/leakage.2

The efficacy of GEMTESA was evaluated in a 12-week, double-blind, randomized, placebo- and active-controlled trial in patients with OAB (UUI, urgency, and urinary frequency). For study entry, patients had to have symptoms of OAB for at least 3 months with an average of 8 or more micturitions per day and at least 1 UUI per day, or an average of 8 or more micturitions per day and an average of at least 3 urgency episodes per day. A total of 1515 patients received at least 1 daily dose of placebo (n=540), GEMTESA 75 mg (n=545), or an active-control treatment (n=430). The majority of patients were Caucasian (78%) and female (85%) with a mean age of 60 (range 18 to 93) years.1,3

Data were based on unadjusted values for a supportive outcome measure that was a prespecified secondary endpoint in the pivotal EMPOWUR trial.3

§In a 12-week pivotal study, hypertension rates for OAB patients taking GEMTESA (n=545) were 1.7% vs 1.7% with placebo (n=540). Increased blood pressure (BP) rates were 0.7% with GEMTESA vs 0.9% with placebo.3

||In a 4-week, randomized, placebo-controlled, ambulatory BP study in OAB patients (n=200), GEMTESA 75 mg was not associated with clinically significant changes in BP. Mean age 59 years; 75% female. At baseline: 35% of subjects had preexisting hypertension; 29% were taking at least 1 concomitant antihypertensive medication.1

GEMTESA demonstrated statistically significant reduction of all 3 key OAB symptoms* vs placebo at 12 weeks— including urgency1,2†

See the randomized, double-blind study results for each symptom:

Water drop icon. Leakage episodes happen when you have a strong need to urinate and leaking or wetting accidents.

Urge urinary incontinence/
leakage

View the data
Urgency sign icon. GEMTESA® helps with the need to urinate immediately.

Urgency

View the data
Circular icon. GEMTESA® helps with frequent urination.

Micturition Frequency

View the data

*The 3 key symptoms of OAB are urgency, micturition frequency, and UUI/leakage.2

The efficacy of GEMTESA was evaluated in a 12-week, double-blind, randomized, placebo- and active-controlled trial in patients with OAB (UUI, urgency, and urinary frequency). For study entry, patients had to have symptoms of OAB for at least 3 months with an average of 8 or more micturitions per day and at least 1 UUI per day, or an average of 8 or more micturitions per day and an average of at least 3 urgency episodes per day. A total of 1515 patients received at least 1 daily dose of placebo (n=540), GEMTESA 75 mg (n=545), or an active-control treatment (n=430). The majority of patients were Caucasian (78%) and female (85%) with a mean age of 60 (range 18 to 93) years.1

 

References:  1. GEMTESA. Prescribing information. Urovant Sciences GmbH; 2020. Accessed January 4, 2021. https://gemtesa.com/sites/default/files/gemtesa-prescribing-information.pdf 2. Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609-623. 3. Data on file. Urovant Sciences GmbH.